Biotech · Private company
Celyad Oncology SA
Track this companyFree. Adds Celyad Oncology SA to your Dealase workspace and tells you when its record changes.
Clinical trials64 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- NKR-2Phase 2 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- NKR-2 cellsPhase 2 · Acute Myeloid Leukemia/Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- CYAD-02Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CYAD-101Phase 1 · Unresectable Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CYAD-211Phase 1 · Relapse/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- EndoxanPhase 1 · Relapse/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- ENDOXANPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FludaraPhase 1 · Relapse/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- FludaraPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRIPhase 1 · Unresectable Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- FOLFOXPhase 1 · Unresectable Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Unresectable Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal CancerPHASE1 · RECRUITING · started Nov 22, 2021ClinicalTrials.gov NCT04991948 · fetched Nov 12, 2026
- Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple MyelomaPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 16, 2020ClinicalTrials.gov NCT04613557 · fetched Nov 12, 2026
- Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02PHASE1 · RECRUITING · started Nov 25, 2019ClinicalTrials.gov NCT04167696 · fetched Nov 12, 2026
- alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cellsPHASE1 · RECRUITING · started Nov 28, 2018ClinicalTrials.gov NCT03692429 · fetched Nov 12, 2026
- DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2PHASE1_PHASE2 · COMPLETED · started Sep 18, 2018ClinicalTrials.gov NCT03466320 · fetched Nov 12, 2026
- A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer IndicationsPHASE1_PHASE2 · UNKNOWN · started Dec 1, 2016ClinicalTrials.gov NCT03018405 · fetched Nov 12, 2026